drugset
drugset / Trial / NCT06974812

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06974812 ↗

Phase 1/2 Recruiting 250 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.

Timeline

Start
2025-04-18
Primary completion
2026-06-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI3014 Unknown 1 mg/kg Intravenous
Subject IBI3014 Unknown 3 mg/kg Intravenous
Subject IBI3014 Unknown 6 mg/kg Intravenous
Subject IBI3014 Unknown 9 mg/kg Intravenous
Subject IBI3014 Unknown 12 mg/kg Intravenous
Subject IBI3014 Unknown 15 mg/kg Intravenous
Subject IBI3014 Unknown 18 mg/kg Intravenous
Subject IBI3014 Unknown 20 mg/kg Intravenous

Indications

No indication recorded.